DIANA: detection assay for diagnostics and drug discovery
managed by IOCB-TTO
TRL: 4
Availability: Licensing
Status: PCT Application
The IOCB TTO s.r.o. is technology transfer office and subsidiary company of IOCB (Institute of Organic Chemistry and Biochemistry AS CR, v.v.i.). The company matches results of the basic research work of IOCB scientists with needs of commercial partners
The IOCB TTO team supports management and decision making processes in Target Research Groups of IOCB e.g. by due diligence analyses, market potential studies and project feasibility evaluation. Moreover, the company is responsible for networking and industry partner search or negotiations of contracts and agreements in the field of intellectual property. An integral part of IOCB TTO’s duties is the organization and development of spin-off companies on IOCB’s technology platform.
The IOCB TTO participates in Center for Development of Original Drugs (CDOD) project funded by Technology Agency of the Czech Republic as a project management responsible member of consortia.
At the IOCB we develop projects related to: oncology, neuroprotection, metabolic diseases and anti-inflammatory diseases. Furthermore, we develop in house screening technologies for library screening of small molecules, synthetic iBodies and we recently developed a peptide synthesizer.
For more information on IOCB-TTO, its work/projects and team can be found under www.iocb-tto.cz
Joint venture established in 1987 by the European Commission (DG GROW) and the Japanese Government (METI) for promoting all forms of industrial, trade and investment cooperation between the EU and Japan.
The EU-Japan Centre’s activities are subject to the allocation of a Grant Agreement by the European Commission for 2024-2026
